LSV Asset Management Sells 207,400 Shares of Lantheus Holdings, Inc. $LNTH

LSV Asset Management reduced its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 73.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 76,400 shares of the medical equipment provider’s stock after selling 207,400 shares during the period. LSV Asset Management owned about 0.11% of Lantheus worth $3,919,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in LNTH. Waterfront Wealth Inc. bought a new stake in shares of Lantheus in the 3rd quarter valued at approximately $950,000. American Assets Inc. bought a new stake in Lantheus in the third quarter valued at $872,000. Axim Planning & Wealth acquired a new position in Lantheus during the third quarter worth $249,000. Gallacher Capital Management LLC lifted its holdings in shares of Lantheus by 228.9% during the third quarter. Gallacher Capital Management LLC now owns 13,388 shares of the medical equipment provider’s stock valued at $687,000 after acquiring an additional 9,317 shares during the period. Finally, Hantz Financial Services Inc. boosted its stake in shares of Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares in the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Trading Up 1.0%

Shares of NASDAQ LNTH opened at $69.38 on Monday. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.29. The company has a 50-day moving average of $66.30 and a two-hundred day moving average of $59.38. The company has a market cap of $4.60 billion, a PE ratio of 29.15 and a beta of -0.08. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Truist Financial raised their price objective on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Mizuho boosted their target price on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $78.00.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.